Site icon AIT365

Press Ganey Names Avanish Mishra, Ph.D., President, Life Sciences

Press Ganey

Press Ganey, the leading provider of experience measurement, analytics, and insights for health systems and health plans, announced the appointment of Dr. Avanish Mishra as President, Life Sciences. Reporting to Patrick T. Ryan, Chairman and CEO of Press Ganey Forsta, Dr. Mishra will drive the next phase of innovation and expansion for the company’s life sciences business.

A globally accomplished executive, Dr. Mishra brings deep scientific and commercial experience, holding senior roles at Thermo Fisher Scientific, Gilead, and Pfizer. In his most recent role as General Manager of Real World Data at Thermo Fisher, he oversaw critical high-growth initiatives, including the company’s global COVID-19 response.

As President of Life Sciences, Dr. Mishra will spearhead Press Ganey’s work to redefine how life sciences companies engage with patients and providers across the product lifecycle—from clinical development through commercial delivery. By harnessing the company’s unmatched expertise in human experience, advanced analytics, and technology, Dr. Mishra will lead efforts to unlock new levels of customer insight, accelerate decision-making, and drive operational efficiency across the life sciences ecosystem.

Also Read: Lunit Partners with Starvision Service GmbH to Revolutionize Radiology in Germany with AI Imaging Solutions

“Avanish is a proven innovator with both the scientific depth and commercial expertise to scale products that solve complex challenges,” Ryan said. “His appointment signals a transformational moment for our company and our partners in life sciences. With Avanish at the helm, we will accelerate the shift toward more personalized, insight-driven engagement strategies that put people—patients, providers, and caregivers—at the center of innovation.”

Throughout his 20+ year career, Dr. Mishra has championed business transformation across the U.S., Japan, and APAC markets. While at Pfizer, he scaled a joint venture from inception to over $400 million in revenue in just three years. He holds a Ph.D. in Pharmacy Administration and has authored numerous publications widely cited in the scientific community.

Source: Businesswire

Exit mobile version